Published in Archives

What's new in the glaucoma world? — Weekly Glance

This is editorially independent content
1 min read

Visiox Pharma announced that the FDA has accepted its new drug application (NDA) for 0.35% brimonidine tartrate (PDP-716) for the treatment of glaucoma.

What is PDP-716?

PDP-716 is a novel once-daily brimonidine formulation that uses Visiox's patented TearAct fine resin technology to provide slow, consistent, and sustained drug release for IOP control throughout the day.

When might PDP-716 be available?

The company has received a PDUFA date of August 2023. Stay tuned.